Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open‐label, extension trial. (2nd June 2022) - Gelbenegger, Georg; Jaeger, Ulrich; Fillitz, Michael; D'Sa, Shirley; Cartwright, Ronwyn; Shafer, Frank; Wardecki, Marek; Wang, Jennifer; Schoergenhofer, Christian; Jilma, Bernd